Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Response to trametinib of histiocytosis with an activating PTPN11 mutation.

Farnault L, Hélias-Rodzewicz Z, Venton G, Fanciullino R, Gabriel S, Mescam L, Haroche J, Donadieu J, Emile JF.

Leuk Lymphoma. 2019 Aug 8:1-4. doi: 10.1080/10428194.2019.1650175. [Epub ahead of print] No abstract available.

PMID:
31393194
2.

Progress towards molecular-based management of childhood Langerhans cell histiocytosis.

Héritier S, Emile JF, Hélias-Rodzewicz Z, Donadieu J.

Arch Pediatr. 2019 Jul;26(5):301-307. doi: 10.1016/j.arcped.2019.05.015. Epub 2019 Jul 4.

PMID:
31281037
3.

Erdheim-Chester disease associated with chronic myelomonocytic leukemia harboring the same clonal mutation.

Bonnet P, Chasset F, Moguelet P, Abisror N, Itzykson R, Bouaziz JD, Hirsch P, Barbaud A, Haroche J, Mekinian A, Hélias-Rodzewicz Z, Clappier E, Fenaux P, Fain O, Tazi A, Emile JF; EMSED and MINHEMON.

Haematologica. 2019 Jun 20. pii: haematol.2019.223552. doi: 10.3324/haematol.2019.223552. [Epub ahead of print]

4.

Erdheim-Chester Disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1.

Razanamahery J, Diamond EL, Cohen-Aubart F, Plate KH, Lourida G, Charlotte F, Hélias-Rodzewicz Z, Goyal G, Go RS, Dogan A, Abdel-Wahab O, Durham B, Ozkaya N, Amoura Z, Emile JF, Haroche J.

Haematologica. 2019 May 23. pii: haematol.2019.216937. doi: 10.3324/haematol.2019.216937. [Epub ahead of print]

5.

Sarcoidosis occurring during BRAF/MEK inhibitors is associated with paradoxical ERK activation in Erdheim-Chester patients.

Amoura A, Haroche J, Emile JF, Barete S, Helias-Rodzewicz Z, Charlotte F, Maisonobe T, Amoura Z, Cohen Aubart F.

J Eur Acad Dermatol Venereol. 2019 Apr 19. doi: 10.1111/jdv.15636. [Epub ahead of print] No abstract available.

PMID:
31002424
6.

Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study.

Héritier S, Barkaoui MA, Miron J, Thomas C, Moshous D, Lambilliotte A, Mazingue F, Kebaili K, Jeziorski E, Plat G, Aladjidi N, Pacquement H, Galambrun C, Brugières L, Leverger G, Mansuy L, Paillard C, Deville A, Pagnier A, Lutun A, Gillibert-Yvert M, Stephan JL, Cohen-Aubart F, Haroche J, Pellier I, Millot F, Gandemer V, Martin-Duverneuil N, Taly V, Hélias-Rodzewicz Z, Emile JF, Hoang-Xuan K, Idbaih A, Donadieu J.

Br J Haematol. 2018 Nov;183(4):608-617. doi: 10.1111/bjh.15577. Epub 2018 Nov 12.

PMID:
30421536
7.

Highly sensitive methods are required to detect mutations in histiocytoses.

Melloul S, Hélias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Fraitag S, Terrones N, Riller Q, Chazal T, Héritier S, Moreau A, Kambouchner M, Copin MC, Donadieu J, Taly V, Amoura Z, Haroche J, Emile JF.

Haematologica. 2019 Mar;104(3):e97-e99. doi: 10.3324/haematol.2018.201194. Epub 2018 Sep 27. No abstract available.

8.

Langerhans Cell Histiocytoma: A Benign Histiocytic Neoplasm of Diverse Lines of Terminal Differentiation.

Dupeux M, Boccara O, Frassati-Biaggi A, Hélias-Rodzewicz Z, Leclerc-Mercier S, Bodemer C, Molina TJ, Emile JF, Fraitag S.

Am J Dermatopathol. 2019 Jan;41(1):29-36. doi: 10.1097/DAD.0000000000001255. Review.

PMID:
30252693
9.

Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab.

Costantini A, Julie C, Dumenil C, Hélias-Rodzewicz Z, Tisserand J, Dumoulin J, Giraud V, Labrune S, Chinet T, Emile JF, Giroux Leprieur E.

Oncoimmunology. 2018 Apr 20;7(8):e1452581. doi: 10.1080/2162402X.2018.1452581. eCollection 2018.

10.

CDKN2A Depletion Causes Aneuploidy and Enhances Cell Proliferation in Non-Immortalized Normal Human Cells.

Hélias-Rodzewicz Z, Lourenco N, Bakari M, Capron C, Emile JF.

Cancer Invest. 2018;36(6):338-348. doi: 10.1080/07357907.2018.1491588. Epub 2018 Aug 23.

PMID:
30136875
11.

Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort.

Cohen-Aubart F, Emile JF, Carrat F, Helias-Rodzewicz Z, Taly V, Charlotte F, Cluzel P, Donadieu J, Idbaih A, Barete S, Amoura Z, Haroche J.

Am J Hematol. 2018 May;93(5):E114-E117. doi: 10.1002/ajh.25055. Epub 2018 Feb 10. No abstract available.

12.

High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis.

Papo M, Diamond EL, Cohen-Aubart F, Emile JF, Roos-Weil D, Gupta N, Durham BH, Ozkaya N, Dogan A, Ulaner GA, Rampal R, Kahn JE, Sené T, Charlotte F, Hervier B, Besnard C, Bernard OA, Settegrana C, Droin N, Hélias-Rodzewicz Z, Amoura Z, Abdel-Wahab O, Haroche J.

Blood. 2017 Aug 24;130(8):1007-1013. doi: 10.1182/blood-2017-01-761718. Epub 2017 Jul 5.

13.

New somatic BRAF splicing mutation in Langerhans cell histiocytosis.

Héritier S, Hélias-Rodzewicz Z, Chakraborty R, Sengal AG, Bellanné-Chantelot C, Thomas C, Moreau A, Fraitag S, Allen CE, Donadieu J, Emile JF.

Mol Cancer. 2017 Jul 6;16(1):115. doi: 10.1186/s12943-017-0690-z.

14.

Variation of mutant allele frequency in NRAS Q61 mutated melanomas.

Hélias-Rodzewicz Z, Funck-Brentano E, Terrones N, Beauchet A, Zimmermann U, Marin C, Saiag P, Emile JF.

BMC Dermatol. 2017 Jul 1;17(1):9. doi: 10.1186/s12895-017-0061-x.

15.

Reply to "Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma" by Mesbah Ardakani et al.

Boespflug A, Funck-Brentano E, Hélias-Rodzewicz Z, Maucort-Boulch D, Beauchet A, Bringuier PP, Dumontet C, Emile JF, Saiag P, Dalle S.

Pigment Cell Melanoma Res. 2017 Sep;30(5):498-500. doi: 10.1111/pcmr.12606. Epub 2017 Jul 23. No abstract available.

PMID:
28627072
16.

Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells.

Durham BH, Roos-Weil D, Baillou C, Cohen-Aubart F, Yoshimi A, Miyara M, Papo M, Hélias-Rodzewicz Z, Terrones N, Ozkaya N, Dogan A, Rampal R, Urbain F, Le Fèvre L, Diamond EL, Park CY, Papo T, Charlotte F, Gorochov G, Taly V, Bernard OA, Amoura Z, Abdel-Wahab O, Lemoine FM, Haroche J, Emile JF.

Blood. 2017 Jul 13;130(2):176-180. doi: 10.1182/blood-2016-12-757377. Epub 2017 May 31.

17.

Circulating cell-free BRAFV600E as a biomarker in children with Langerhans cell histiocytosis.

Héritier S, Hélias-Rodzewicz Z, Lapillonne H, Terrones N, Garrigou S, Normand C, Barkaoui MA, Miron J, Plat G, Aladjidi N, Pagnier A, Deville A, Gillibert-Yvert M, Moshous D, Lefèvre-Utile A, Lutun A, Paillard C, Thomas C, Jeziorski E, Nizard P, Taly V, Emile JF, Donadieu J.

Br J Haematol. 2017 Aug;178(3):457-467. doi: 10.1111/bjh.14695. Epub 2017 Apr 25.

PMID:
28444728
18.

Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas.

Pilati C, Shinde J, Alexandrov LB, Assié G, André T, Hélias-Rodzewicz Z, Ducoudray R, Le Corre D, Zucman-Rossi J, Emile JF, Bertherat J, Letouzé E, Laurent-Puig P.

J Pathol. 2017 May;242(1):10-15. doi: 10.1002/path.4880. Epub 2017 Mar 29.

PMID:
28127763
19.

BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.

Héritier S, Emile JF, Barkaoui MA, Thomas C, Fraitag S, Boudjemaa S, Renaud F, Moreau A, Peuchmaur M, Chassagne-Clément C, Dijoud F, Rigau V, Moshous D, Lambilliotte A, Mazingue F, Kebaili K, Miron J, Jeziorski E, Plat G, Aladjidi N, Ferster A, Pacquement H, Galambrun C, Brugières L, Leverger G, Mansuy L, Paillard C, Deville A, Armari-Alla C, Lutun A, Gillibert-Yvert M, Stephan JL, Cohen-Aubart F, Haroche J, Pellier I, Millot F, Lescoeur B, Gandemer V, Bodemer C, Lacave R, Hélias-Rodzewicz Z, Taly V, Geissmann F, Donadieu J.

J Clin Oncol. 2016 Sep 1;34(25):3023-30. doi: 10.1200/JCO.2015.65.9508. Epub 2016 Jul 5.

20.

Increase in NRAS mutant allele percentage during metastatic melanoma progression.

Funck-Brentano E, Hélias-Rodzewicz Z, Longvert C, Mokhtari K, Saiag P, Emile JF.

Exp Dermatol. 2016 Jun;25(6):472-4. doi: 10.1111/exd.13001. Epub 2016 May 18.

PMID:
26990546
21.

Variations of BRAF mutant allele percentage in melanomas.

Hélias-Rodzewicz Z, Funck-Brentano E, Baudoux L, Jung CK, Zimmermann U, Marin C, Clerici T, Le Gall C, Peschaud F, Taly V, Saiag P, Emile JF.

BMC Cancer. 2015 Jul 4;15:497. doi: 10.1186/s12885-015-1515-3.

22.

Copy-neutral loss of heterozygosity and chromosome gains and losses are frequent in gastrointestinal stromal tumors.

Lourenço N, Hélias-Rodzewicz Z, Bachet JB, Brahimi-Adouane S, Jardin F, Tran van Nhieu J, Peschaud F, Martin E, Beauchet A, Chibon F, Emile JF.

Mol Cancer. 2014 Nov 6;13:246. doi: 10.1186/1476-4598-13-246.

23.

Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease.

Emile JF, Diamond EL, Hélias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Hyman DM, Kim E, Rampal R, Patel M, Ganzel C, Aumann S, Faucher G, Le Gall C, Leroy K, Colombat M, Kahn JE, Trad S, Nizard P, Donadieu J, Taly V, Amoura Z, Abdel-Wahab O, Haroche J.

Blood. 2014 Nov 6;124(19):3016-9. doi: 10.1182/blood-2014-04-570937. Epub 2014 Aug 22.

24.

Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group.

Emile JF, Tisserand J, Bergougnoux L, Nowak F, Faucher G, Surel S, Lamy A, Lecorre D, Helias-Rodzewicz Z, Hofman P, Sabourin JC, Laurent-Puig P; BRAF EQA Group.

BMC Cancer. 2013 Oct 11;13:472. doi: 10.1186/1471-2407-13-472.

25.

Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.

Colomba E, Hélias-Rodzewicz Z, Von Deimling A, Marin C, Terrones N, Pechaud D, Surel S, Côté JF, Peschaud F, Capper D, Blons H, Zimmermann U, Clerici T, Saiag P, Emile JF.

J Mol Diagn. 2013 Jan;15(1):94-100. doi: 10.1016/j.jmoldx.2012.09.001. Epub 2012 Nov 15.

PMID:
23159108
26.

High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.

Haroche J, Charlotte F, Arnaud L, von Deimling A, Hélias-Rodzewicz Z, Hervier B, Cohen-Aubart F, Launay D, Lesot A, Mokhtari K, Canioni D, Galmiche L, Rose C, Schmalzing M, Croockewit S, Kambouchner M, Copin MC, Fraitag S, Sahm F, Brousse N, Amoura Z, Donadieu J, Emile JF.

Blood. 2012 Sep 27;120(13):2700-3. Epub 2012 Aug 9.

27.

Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.

Moreau S, Saiag P, Aegerter P, Bosset D, Longvert C, Hélias-Rodzewicz Z, Marin C, Peschaud F, Chagnon S, Zimmermann U, Clerici T, Emile JF.

Ann Surg Oncol. 2012 Dec;19(13):4314-21. doi: 10.1245/s10434-012-2457-5. Epub 2012 Jul 7.

PMID:
22772867
28.

YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas.

Hélias-Rodzewicz Z, Pérot G, Chibon F, Ferreira C, Lagarde P, Terrier P, Coindre JM, Aurias A.

Genes Chromosomes Cancer. 2010 Dec;49(12):1161-71. doi: 10.1002/gcc.20825.

PMID:
20842732
29.

Selective elimination of amplified CDK4 sequences correlates with spontaneous adipocytic differentiation in liposarcoma.

Hélias-Rodzewicz Z, Pédeutour F, Coindre JM, Terrier P, Aurias A.

Genes Chromosomes Cancer. 2009 Nov;48(11):943-52. doi: 10.1002/gcc.20696.

PMID:
19626636
30.

[Familial subtelomeric abnormality der(4)t(4p16.3;21q22.3) as a cause of mental retardation and mild dysmorphic features].

Obersztyn E, Klapecki J, Helias-Rodzewicz Z, Bocian E, Mazurczak T.

Med Wieku Rozwoj. 2006 Jan-Mar;10(1 Pt 2):199-209. Polish.

PMID:
17028389
31.

[Subtelomeric aberration as a cause of severe somatic and psychomotor retardation in a child with dysmorphic features and CNS defects].

Kutkowska-Kaźmierczak A, Obersztyn E, Helias-Rodzewicz Z, Bocian E, Mazurczak T.

Med Wieku Rozwoj. 2004 Oct-Dec;8(4 Pt 1):949-62. Polish.

PMID:
15951614
32.

Subtelomeric rearrangements: results from FISH studies in 84 families with idiopathic mental retardation.

Bocian E, Hélias-Rodzewicz Z, Suchenek K, Obersztyn E, Kutkowska-Kaźmierczak A, Stankiewicz P, Kostyk E, Mazurczak T.

Med Sci Monit. 2004 Apr;10(4):CR143-51.

PMID:
15039644
33.

[Case of subtelomeric aberration as a cause of familial intellectual disability with congenital defects and dysmorphic features--problems of diagnosis and genetic counseling].

Obersztyn E, Mazurczak T, Helias-Rodzewicz Z, Bocian E, Kutkowska-Kazmierczak A.

Med Wieku Rozwoj. 2003 Jul-Sep;7(3):389-401. Polish.

PMID:
14963346
34.

Subtelomeric rearrangements detected by FISH in three of 33 families with idiopathic mental retardation and minor physical anomalies.

Hélias-Rodzewicz Z, Bocian E, Stankiewicz P, Obersztyn E, Kostyk E, Jakubów-Durska K, Kutkowska-Kaźmierczak A, Mazurczak T.

J Med Genet. 2002 Sep;39(9):e53. No abstract available.

35.

Clinical and molecular-cytogenetic studies in seven patients with ring chromosome 18.

Stankiewicz P, Brozek I, Hélias-Rodzewicz Z, Wierzba J, Pilch J, Bocian E, Balcerska A, Wozniak A, Kardaś I, Wirth J, Mazurczak T, Limon J.

Am J Med Genet. 2001 Jul 1;101(3):226-39.

PMID:
11424138
36.

Cytogenetic and molecular characterization of two isodicentric Y chromosomes.

Stankiewicz P, Hélias-Rodzewicz Z, Jakubów-Durska K, Bocian E, Obersztyn E, Rappold GA, Mazurczak T.

Am J Med Genet. 2001 Jun 1;101(1):20-5.

PMID:
11343332

Supplemental Content

Loading ...
Support Center